Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

Post by retiredcfon Apr 05, 2023 9:53am
196 Views
Post# 35380749

Globe & Mail

Globe & Mail

08:04 AM EDT, 04/05/2023 (MT Newswires) -- Opsens Inc. (OPS.TO), a cardiology-focused medical device company, said Wednesday that its SavvyWire solution has been successfully used by physicians in 1,000 procedures.

Opsens said SavvyWire is a sensor-guided solution for transcatheter aortic valve replacement procedures to treat aortic valve stenosis.

"The successful use of the SavvyWire in 1,000 patients marks an important milestone towards full-scale commercialization of our innovative device," President and CEO Louis Laflamme said.

"The early commercialization phase is progressing steadily and the impressive number of procedures completed demonstrates the acceptance and relevance of the SavvyWire within the structural heart market."

<< Previous
Bullboard Posts
Next >>